Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Alvotech Beats Back AbbVie's Trade Secrets Lawsuit
2 Twelve-Month Court Battle Will Delay Adalimumab Biosimilar Launch for Alvotech
3 Federal Judge Dismisses AbbVie Trade Secrets Case Against Alvotech
4 Litigation and Regulatory Update for Alvotech’s Adalimumab Biosimilar
5 AbbVie's Trade Secrets Case Against Alvotech Tossed by Judge
6 AbbVie Trade Secret Claims Fail at Pleading Stage for Lack of Jurisdiction
7 AbbVie suffers knock-back in Humira trade secrets dispute | IAM
8 Virginia Judge Ships Suit Over AbbVie's Humira To Illinois
9 End-to-End Continuous Processing is Technically Possible
10 Alvotech Sees AbbVie's Humira Trade Secrets Case Thrown Out In US
11 FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody
12 FDA Approves Boehringer Ingelheim's Cyltezo® as Interchangeable with Humira®
13 Case: Trade Secrets/Jurisdiction (N.D. Ill.)
14 The Top 5 Biosimilar Articles for the Week of October 11
15 Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®
16 Alvotech Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn
17 Other news to note for Oct. 11, 2021 | 2021-10-11
18 Expect a dramatic finale to the Humira patent saga | IAM
19 Alvotech Provides Update on FDA Action Regarding AVT02, Proposed High-Concentration Biosimilar to Humira® (adalimumab)
20 Alvotech Completes Second Round of a US$ 100m Private Placement
21 Boehringer's interchangeable tag for Humira biosim is a 'landmark' win for the field: analyst
22 Alvotech Welcomes Positive CHMP Opinion for AVT02, a Proposed Biosimilar to Humira®
23 FDA Delays Review of Alvotech's AVT02 Adalimumab Biosimilar Candidate
24 Alvotech Seeks to End AbbVie's Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.
25 Alvotech Announces Reaching the Primary Completion Date in Its AVT02 Switching Study
26 Alvotech Reaches Primary Completion Date in Its Switching Study for AVT02, a Proposed Interchangeable Biosimilar to AbbVie's Humira®
27 Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
28 US FDA approval tracker: September
29 Alvotech Initiates Clinical Studies for AVT04, a Proposed Biosimilar to Stelara® (Ustekinumab)
30 AbbVie Legal Complaint Alleges Alvotech Misappropriated Humira Trade Secrets
31 Alvotech Disputes AbbVie's Recent Allegations
32 AbbVie Files Second Suit Against Alvotech For Patent Infringement Under the BPCIA
33 Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical Agree on an Exclusive Biosimilar Partnership in China
34 Alvotech challenges AbbVie on US Humira exclusivity
35 FDA Grants Interchangeable Status for Boehringer Ingelheim's Adalimumab Biosimilar (Cyltezo)
36 Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
37 CHMP adopts positive opinion on Alvotech’s adalimumab biosimilar
38 An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
39 Alvotech breaks Ground for Biosimilar Development Facility
40 Alvotech Suffers Delay On Higher-Strength Adalimumab In US
41 Alvotech Value Rises Again As Portion Of Debt Is Wiped Away
42 Alvotech Announces Clinical Studies for Ustekinumab Biosimilar
43 Alvotech Announces Private Placement Financing
44 Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
45 The Top 5 Biosimilar Articles for the Week of September 27
46 Northern District of Illinois Holds That a Biosimilar Applicant Is Not a Necessary Party to a BPCIA Lawsuit
47 AbbVie confident of fighting off Alvotech challenge on Humira
48 AbbVie Humira Lawsuit Withstands Alvotech Attack :: Generics Bulletin
49 Alvotech Files for US and EU Approval of Adalimumab Biosimilar
50 Illinois court rejects dismissal of AbbVie patent case
51 AbbVie Sues Alvotech Again Alleging At-Risk Adalimumab Launch
52 Pearce IP BioBlast®: w/e 08 October 2021
53 Adalimumab Biosimilar Shows Equivalent Efficacy, Safety to Reference Humira for Psoriasis
54 Alvotech Welcomes Stelara Biosimilar Into Phase III Development
55 Alvotech files lawsuit challenging AbbVie's Humira patent thicket
56 Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
57 Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
58 Biden highlights vaccine mandates in Chicago • New hiring in budget for Cook County Health • Pediatric COVID vaccines on the way
59 Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand
60 Alvotech and Cipla Partner on 5 Biosimilars for South Africa
61 What's Next? Five Things To Look Out For In September
62 Alvotech Raises $300 Million to Develop Biosimilars
63 Alvotech Expands Agreement with DKSH
64 Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close
65 Alvotech Reports Efficacy and PK Results for AVT02
66 Biosimilar Market Updates: Samsung Biologics, Celltrion, and Alvotech
67 Alvotech raises $300m to advance biosimilar pipelineBioProcess International
68 New Humira decision changes venue selection playbook for US biosimilar patent disputes | IAM
69 Fuji Pharma Invests in Alvotech for US$50 Million
70 Drugmaker CEO Cleared After Former Executive Alleged Bullying
71 Icelandic Biopharmaceutical Company Alvotech Signs Huge Contract with Teva
72 First Edition: Oct. 8, 2021
73 Alvotech to Manufacture Prestige's Biosimilars
74 Yas Holding Invests in Alvotech and Agrees on a Strategic Partnership for Biosimilar Candidates
75 N.D. Ill. Finds that a Foreign Parent Corp. May be Sued Under BPCIA Without the U.S. Subsidiary that Signed and Filed aBLA
76 Friday, October 8, 2021
77 Alvotech, Prestige Biopharma Enter New Manufacturing Partnership
78 Alvotech Hf and DKSH Announce Plans to Bring an Adalimumab Biosimilar to Market
79 Teva ties up agreement with Alvotech to commercialize five biosimilars
80 AbbVie accuses company of recruiting employee to steal Humira secrets
81 Alvotech and Cipla partner on Humira biosimilar
82 Adalimumab Biosimilars Face Product Obsolescence Before Launch
83 Alvotech Raises $300M To Fuel Biosimilar Growth
84 Alvotech Enrolls First Patient in Phase 3 Study of Proposed High-Concentration Biosimilar Adalimumab
85 JAMP Pharma Licenses 5 Biosimilar Candidates From Alvotech for Canadian Market
86 Tanya Zharov vows to help strengthen Alvotech as leader in biosimilars
87 Iceland's Alvotech partners with China's Changchun to develop biosimilars
88 Alvotech signs supply agreement with Fuji Pharma
89 iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink
90 Alvotech invests $250 million in biopharmaceuticals | FiercePharma
91 Alvotech And DKSH Extend Biosimilar Partnership In Asia
92 Alvotech, Cipla Gulf Ink Biosimilar Deal
93 Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up
94 Chemocentryx's Tavneos wins FDA nod for ANCA-associated vasculitis
95 Hospitals look for advance payment • Northwestern opens neurosciences at Palos Hospital
96 Alvotech Announces Acquisition of Baliopharm
97 Bio-Thera Conducts Simponi Phase III Trial
98 Court upholds AbbVie's patents on blockbuster cancer drug Imbruvica, generics unlikely until 2032
99 Alvotech, JAMP Pharma Ink Biosim Deal
100 Alvotech Opens State-of-the-Art Biosimilar Facility in Iceland